HRP20171640T1 - Monoklonska protutijela za receptor faktora rasta fibroblasta 2 - Google Patents

Monoklonska protutijela za receptor faktora rasta fibroblasta 2

Info

Publication number
HRP20171640T1
HRP20171640T1 HRP20171640TT HRP20171640T HRP20171640T1 HR P20171640 T1 HRP20171640 T1 HR P20171640T1 HR P20171640T T HRP20171640T T HR P20171640TT HR P20171640 T HRP20171640 T HR P20171640T HR P20171640 T1 HRP20171640 T1 HR P20171640T1
Authority
HR
Croatia
Prior art keywords
growth factor
monoclonal antibodies
factor receptor
fibroblast growth
fibroblast
Prior art date
Application number
HRP20171640TT
Other languages
English (en)
Croatian (hr)
Inventor
Kyung Jin Kim
Wei-Meng Zhao
Hangil Park
Original Assignee
Galaxy Biotech, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galaxy Biotech, Llc filed Critical Galaxy Biotech, Llc
Publication of HRP20171640T1 publication Critical patent/HRP20171640T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HRP20171640TT 2008-11-07 2017-10-26 Monoklonska protutijela za receptor faktora rasta fibroblasta 2 HRP20171640T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11268608P 2008-11-07 2008-11-07
US16487009P 2009-03-30 2009-03-30
EP14188785.1A EP2842573B1 (en) 2008-11-07 2009-11-06 Monoclonal antibodies to Fibroblast Growth Factor receptor 2

Publications (1)

Publication Number Publication Date
HRP20171640T1 true HRP20171640T1 (hr) 2018-01-12

Family

ID=42153600

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20171640TT HRP20171640T1 (hr) 2008-11-07 2017-10-26 Monoklonska protutijela za receptor faktora rasta fibroblasta 2
HRP20200090TT HRP20200090T1 (hr) 2008-11-07 2020-01-20 Monoklonska protutijela protiv receptora 2 čimbenika rasta fibroblasta

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20200090TT HRP20200090T1 (hr) 2008-11-07 2020-01-20 Monoklonska protutijela protiv receptora 2 čimbenika rasta fibroblasta

Country Status (20)

Country Link
US (8) US8101723B2 (enExample)
EP (4) EP2365828B1 (enExample)
JP (8) JP5627591B2 (enExample)
KR (1) KR101699432B1 (enExample)
CN (1) CN102131524B (enExample)
AU (1) AU2009313357B2 (enExample)
BR (1) BRPI0917315B8 (enExample)
CA (2) CA2733668C (enExample)
DK (3) DK2842573T3 (enExample)
ES (3) ES2646168T3 (enExample)
HR (2) HRP20171640T1 (enExample)
HU (1) HUE035700T2 (enExample)
LT (2) LT3290052T (enExample)
MX (1) MX2011000455A (enExample)
NO (1) NO2842573T3 (enExample)
PL (3) PL3290052T3 (enExample)
PT (3) PT2842573T (enExample)
RU (1) RU2546254C9 (enExample)
SI (2) SI2842573T1 (enExample)
WO (1) WO2010054265A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110059091A1 (en) * 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
CN102131524B (zh) 2008-11-07 2014-05-14 星系生物科技责任有限公司 成纤维细胞生长因子受体2的单克隆抗体
KR20130065665A (ko) 2010-05-11 2013-06-19 아베오 파마슈티컬즈, 인크. 항-fgfr2 항체
EP2603521A4 (en) * 2010-08-12 2014-10-01 Attogen Inc ANTIBODY MOLECULARS FOR ONGOGEN FIBROBLAST GROWTH RECEPTOR 2 ISOFORMS AND ITS USES
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
RU2014128467A (ru) * 2011-12-14 2016-02-10 Сиэтл Дженетикс, Инк. Новые коньюгаты связывающее соединение-активное соединение (adc) и их применение
KR102050615B1 (ko) * 2012-03-08 2019-11-29 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 b 바이러스들에 결합하고 중화할 수 있는 인간 결합 분자 및 그 용도
BR112014025037A2 (pt) * 2012-04-09 2018-07-31 Daiichi Sankyo Company, Limited anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
WO2014089193A1 (en) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
SI2936153T1 (sl) * 2012-12-21 2019-02-28 Janssen Biotech, Inc. Občutljiv multipleksni imunski test za topen rastni faktor fibroblasta
CN103145843B (zh) * 2013-02-20 2014-10-29 暨南大学 抗成纤维细胞生长因子受体的单链抗体
RU2015137610A (ru) 2013-03-06 2017-04-10 Дженентек, Инк. Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
PH12019501393B1 (en) * 2013-08-01 2022-09-07 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
WO2015053407A1 (ja) * 2013-10-08 2015-04-16 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤の組合せ
CN103757026B (zh) * 2013-12-20 2017-04-05 广州圣露生物技术有限公司 FGFR2b胞外段的基因序列、多肽及其应用
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
CN104231079A (zh) * 2014-09-12 2014-12-24 暨南大学 一种靶向bFGF高亲和力受体结合位点的抗体及其应用
JP6887944B2 (ja) * 2015-04-08 2021-06-16 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤を含む組成物
JPWO2016171107A1 (ja) 2015-04-20 2018-03-22 第一三共株式会社 Ｆｇｆｒ２の検出
RU2638457C2 (ru) * 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
JP7349787B2 (ja) 2015-11-23 2023-09-25 ファイヴ プライム セラピューティクス インク 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
WO2018213304A1 (en) 2017-05-16 2018-11-22 Five Prime Therapeutics, Inc. Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
WO2018220225A1 (en) 2017-06-02 2018-12-06 Ablynx Nv Aggrecan binding immunoglobulins
AU2018354189A1 (en) 2017-10-24 2020-04-23 Crispr Therapeutics Ag Compositions and methods for the depletion of CD117+ cells
KR20200069364A (ko) 2017-10-24 2020-06-16 마젠타 테라퓨틱스 인코포레이티드 Cd117+ 세포의 고갈을 위한 조성물 및 방법
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
CN112804989A (zh) 2018-10-05 2021-05-14 戊瑞治疗有限公司 抗fgfr2抗体制剂
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
KR20220119144A (ko) * 2019-12-24 2022-08-26 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 신규한 항fgfr2b 항체
JP7686000B2 (ja) * 2019-12-24 2025-05-30 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド 新規抗ＦＧＦＲ２ｂ抗体
WO2021247718A1 (en) * 2020-06-03 2021-12-09 The Broad Institute, Inc. Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same
NZ797493A (en) 2020-10-22 2024-05-31 Regeneron Pharma Anti-fgfr2 antibodies and methods of use thereof
KR20230129456A (ko) * 2020-12-29 2023-09-08 선전 포워드 파머수티컬즈 코 엘티디 항-fgfr2 항체 및 이의 용도
US20250277041A1 (en) * 2021-10-08 2025-09-04 Shenzhen Forward Pharmaceuticals Co., Limited Anti-fgfr2 adcc enhanced antibody and use thereof
TW202342527A (zh) 2022-02-25 2023-11-01 美商安進公司 鱗狀非小細胞肺癌之治療
KR20250099773A (ko) * 2022-09-30 2025-07-02 3에이치 파머슈티컬즈 컴퍼니 리미티드 항-fgfr2b 항체 및 이의 용도
CN118852431A (zh) * 2023-04-28 2024-10-29 武汉人福创新药物研发中心有限公司 抗FGFR2b单抗
WO2024240107A1 (zh) * 2023-05-19 2024-11-28 广东东阳光药业股份有限公司 一种抗fgfr2抗体及其应用
WO2024255756A1 (zh) * 2023-06-13 2024-12-19 南京维立志博生物科技股份有限公司 基于共同轻链产生双特异性抗体的方法
WO2025130905A1 (zh) * 2023-12-18 2025-06-26 山东先声生物制药有限公司 抗FGFR2b抗体-药物缀合物及其应用
WO2025218662A1 (zh) * 2024-04-16 2025-10-23 杭州中美华东制药有限公司 抗成纤维细胞生长因子受体2b的抗体及其用途
TW202547875A (zh) * 2024-05-09 2025-12-16 大陸商正大天晴藥業集團股份有限公司 靶向成纖維細胞生長因子受體2IIIb的抗體及其應用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
HU215581B (hu) 1989-07-06 1999-01-28 Regents Of The University Of California Eljárás fibroblaszt növekedési faktor receptorok előállítására és terápiás alkalmazására
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5863888A (en) 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
KR960704938A (ko) * 1993-10-14 1996-10-09 그리스토퍼 엘. 와이트 Fas 길항제 및 그의 용도(Fas Antagonists and Uses Thereof)
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
AU3494397A (en) 1996-06-18 1998-01-07 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Fibroblast growth factor receptor activating gene i and related compositions and methods
US20030143676A1 (en) 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use
ES2223705T3 (es) * 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
JP2001302699A (ja) 2000-04-17 2001-10-31 Nichirei Corp ヒトｋｇｆｒに対する抗体
US20020115603A1 (en) 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
JP4298498B2 (ja) * 2001-06-13 2009-07-22 ゲンマブ エー／エス 上皮成長因子受容体（ｅｇｆｒ）に対するヒトモノクローナル抗体
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
JP2005530687A (ja) 2002-01-31 2005-10-13 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Ｆｇｆｒアゴニスト
KR100493460B1 (ko) * 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 ｆｇｆｒ2 이성체
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
MXPA06000508A (es) 2003-07-18 2006-04-05 Amgen Inc Agentes de union especifica al factor del crecimiento de los hepatocitos.
EP1697420A2 (en) * 2003-12-19 2006-09-06 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
EP1773305A2 (en) 2004-05-25 2007-04-18 Yale University Corporation Method for treating skeletal disorders resulting from fgfr malfunction
EP2041575A2 (en) 2006-03-31 2009-04-01 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
EP2018442A2 (en) * 2006-05-12 2009-01-28 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
ATE495195T1 (de) 2006-06-02 2011-01-15 Aveo Pharmaceuticals Inc Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e
ES2378097T3 (es) 2006-06-02 2012-04-04 Aveo Pharmaceuticals, Inc. Proteínas de unión al factor de crecimiento de hepatocitos (HGF)
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
CA2664738C (en) 2006-09-29 2017-03-07 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2008052796A1 (en) * 2006-11-03 2008-05-08 U3 Pharma Gmbh Fgfr4 antibodies
JP2010525301A (ja) * 2007-03-23 2010-07-22 ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート 子宮内膜癌および前癌の診断、分類および治療の方法
WO2009052830A1 (en) 2007-10-22 2009-04-30 Genmab A/S Novel antibody therapies
US20110059091A1 (en) 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
CN102131524B (zh) 2008-11-07 2014-05-14 星系生物科技责任有限公司 成纤维细胞生长因子受体2的单克隆抗体
WO2011025814A1 (en) 2009-08-25 2011-03-03 National Jewish Health Methods and compositions for treatment of lung injury

Also Published As

Publication number Publication date
EP2365828B1 (en) 2014-10-15
EP2842573A1 (en) 2015-03-04
JP6445496B2 (ja) 2018-12-26
US20100196364A1 (en) 2010-08-05
DK2842573T3 (en) 2017-10-30
HRP20200090T1 (hr) 2020-04-03
EP2842573B1 (en) 2017-09-27
WO2010054265A2 (en) 2010-05-14
CA3166399A1 (en) 2010-05-14
BRPI0917315B1 (pt) 2020-12-08
US8603987B2 (en) 2013-12-10
JP2020096615A (ja) 2020-06-25
JP6661734B2 (ja) 2020-03-11
WO2010054265A3 (en) 2010-09-16
US20200347141A1 (en) 2020-11-05
EP3783024A1 (en) 2021-02-24
PL2365828T3 (pl) 2015-04-30
US20190153105A1 (en) 2019-05-23
CN102131524A (zh) 2011-07-20
US10138301B2 (en) 2018-11-27
PT2842573T (pt) 2017-12-04
RU2011141890A (ru) 2013-04-27
EP2365828A4 (en) 2012-06-06
JP5627591B2 (ja) 2014-11-19
JP2019052165A (ja) 2019-04-04
PT2365828E (pt) 2014-12-12
PL3290052T3 (pl) 2020-06-29
KR101699432B1 (ko) 2017-01-24
SI3290052T1 (sl) 2020-07-31
CA2733668A1 (en) 2010-05-14
US20160362496A1 (en) 2016-12-15
BRPI0917315A2 (pt) 2015-11-17
US20180094063A1 (en) 2018-04-05
ES2523740T3 (es) 2014-12-01
JP2014240385A (ja) 2014-12-25
JP7301106B2 (ja) 2023-06-30
JP6342223B2 (ja) 2018-06-13
EP3290052A1 (en) 2018-03-07
NO2842573T3 (enExample) 2018-02-24
RU2546254C2 (ru) 2015-04-10
HUE035700T2 (en) 2018-05-28
HK1160012A1 (en) 2012-08-10
PL2842573T3 (pl) 2018-04-30
US20120134994A1 (en) 2012-05-31
KR20110081141A (ko) 2011-07-13
JP6960485B2 (ja) 2021-11-05
SI2842573T1 (en) 2018-01-31
US20230242650A1 (en) 2023-08-03
US8101723B2 (en) 2012-01-24
AU2009313357B2 (en) 2015-06-11
PT3290052T (pt) 2020-02-06
BRPI0917315B8 (pt) 2021-05-25
MX2011000455A (es) 2011-02-25
RU2546254C9 (ru) 2015-07-10
DK3290052T3 (da) 2020-02-03
JP2025032085A (ja) 2025-03-11
DK2365828T3 (en) 2014-12-08
ES2646168T3 (es) 2017-12-12
EP2365828A2 (en) 2011-09-21
JP2012508184A (ja) 2012-04-05
HK1249053A1 (en) 2018-10-26
US9382324B2 (en) 2016-07-05
JP2017019807A (ja) 2017-01-26
HK1207974A1 (en) 2016-02-19
LT2842573T (lt) 2017-12-11
ES2770134T3 (es) 2020-06-30
EP3290052B1 (en) 2019-12-25
AU2009313357A1 (en) 2010-05-14
LT3290052T (lt) 2020-02-25
CN102131524B (zh) 2014-05-14
CA3166399C (en) 2026-02-03
JP2023116746A (ja) 2023-08-22
US10689448B2 (en) 2020-06-23
JP2022008996A (ja) 2022-01-14
US9834609B2 (en) 2017-12-05
CA2733668C (en) 2022-08-30
US20140193899A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
HRP20171640T1 (hr) Monoklonska protutijela za receptor faktora rasta fibroblasta 2
LTPA2018017I1 (lt) Žmogaus CGRP receptorių rišantys antikūnai
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
DK2131860T3 (da) Anti-sclerostin-antistoffer
PT2195026E (pt) Anticorpos anti-esclerostina
BRPI0918768A2 (pt) composições de anticorpo recombinante de anti-receptor do fator de crescimento epidérmico.
HRP20150086T1 (xx) Humanizirana antitijela za beta amiloid
EP2254911A4 (en) HUMANIZED ANTI-C5aR ANTIBODIES
CR20170001A (es) Anticuerpos anti factor d humanizados
BRPI0923359A2 (pt) Anticorpos anti-igf
EP2324359A4 (en) MONOCLONAL ANTIBODY STRO-4
BRPI0819165A2 (pt) Anticorpos anti-vegf
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
PL3059246T3 (pl) Zmodyfikowany region stały przeciwciała
EP2331579A4 (en) MONOCLONAL ANTIBODIES
EP2501800A4 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN NUCLEOLIN
EP2206775A4 (en) ANTI-IL-6 receptor antibody
SMT201700083B (it) Anticorpi monoclonali
DK2344537T3 (da) Bispecifikke anti-vegf/anti-ang-2-antistoffer
DK2066695T3 (da) Anti-myostatin-antistoffer
DK2158217T3 (da) Humant monoklonalt antistof, der neutraliserer vaskulær endotel vækstfaktorreceptor, og anvendelse heraf
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
HRP20180485T1 (hr) Monoklonska antitijela za gt468 za liječenje raka
BRPI0916092A2 (pt) "isoformas específicas de anticorpos anti-her4"
BRPI0814116A2 (pt) Anticorpo monoclonal citotóxico anticâncer